Homepage > Company > Media > Pharma News > 2020 > Mouthwash can kill coronavirus within 30 seconds: Research

Mouthwash can kill coronavirus within 30 seconds: Research

Cardiff University researchers found that mouthwash emanating from the mouth contained 0.07% Cetyl Pyridinium Chloride (CPC), which showed "promising signs" of reducing COVID-19.

According to an experimental study, the mouthwash exhibited virgin properties that could kill the deadly coronavirus. Researchers say that mouthwash can reduce the oral "viral load" of SARS-CoV-2, which causes COVID-19 in people suffering from the disease. The initial result follows from a clinical trial whether the patient can reduce COVID-19 levels in saliva using over-the-counter mouthwash.

Skeletal formula of cetylpyridinium cation with a chloride anion

Cetylpyridinium chloride

A WION report says, Cardiff University researchers found that mouthwash emanating from the mouth contained 0.07% Cetyl Pyridinium Chloride (CPC), which showed "promising signs" of reducing COVID-19.

Dentyl will be the only UK mouthwash brand used in the trial, and the findings will be published in early 2021.

Nov 17, 2020

https://www.dnaindia.com/health/

Read also

FDA Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has declined to issue an Emergency Use Authoriz...

U.S. Government Inks $3.2 Billion Contract With Pfizer-BioNTech for Vaccine Booster Campaign

The U.S. government has signed a $3.2 billion COVID-19 vaccine supply agreement with Pfizer and BioNTech for 105 million doses.

FDA Pushes Back Review Period for Provention Bio's Diabetes Drug

Provention Bio will have to wait a little bit longer to see if the U.S. Food and Drug Administration will approve its diabetes prevention drug, teplizumab.

FDA rejection of Spero’s tebipenem ‘raises resistance threat’

The FDA’s decision not to approve Spero Therapeutics’ oral antibiotic tebipenem Hbr for adults with complicated urinary tract infections (cUTI) further increases the threat of antibiotic resis...